Sanofi(SNY) - 2024 Q4 - Annual Report

Press Release Sanofi: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025 Paris, January 30, 2025 Q4: sales growth of 10.3% at CER and business EPS of €1.31 1 2 FY: double-digit sales growth and business EPS guidance exceeded Pipeline: increased investment and progress • Q4: four regulatory approvals: Dupixent EoE (children) (EU), Kevzara PMR (EU), Cerdelga GD1 (children) (EU), Efluelda flu (JP) 3 • FY: 14 regulatory approvals of medicines and vacc ...